1. Bisphosphonate exposure and Atypical Femoral Fractures
JBMR 2012;27:2544 (Figs. 4, 2)
Reproduced from J Bone Miner Res 2012;27: with permission of the American Society of Bone and Mineral Research.

2. Cortical thickness and Atypical Fractures
Osteoporos Int 2012;23:2893 (Fig. 1)
Reproduced from Osteoporos Int 2012;23: with permission from Springer.

3. N Engl J Med 2012;367:1714 (Fig. 2)
From N Engl J Med, Steven Boonen, Jean-Yves Reginster, Jean-Marc Kaufman, et al., Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis, Volume 367, Page Copyright © (2012) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

4. *p<0.05 vs baseline p<0.001 vs placebo
N Engl J Med 2012;367:1714 (Fig. 3)
From N Engl J Med, Steven Boonen, Jean-Yves Reginster, Jean-Marc Kaufman, et al., Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis, Volume 367, Page Copyright © (2012) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

5. Bone 2012;50:1115 (Fig. 2)
Reproduced from Bone, 50: , Copyright (2012), with permission from Elsevier.

6. Bone 2012;50:1115 (Figs. 4, 5)
Reproduced from Bone, 50: , Copyright (2012), with permission from Elsevier.

7. 1-year fracture incidence by age
Types of fractures
Osteoporos Int 2012;23:2863 (Figs. 1, 3)
Reproduced from Osteoporos Int 2012;23: with permission from Springer.